Synergy Pharmaceuticals Announces Pricing Of Private Offering Of $175 Million Of 7.50% Convertible Senior Notes

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019. The Company also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on and including the first date of the original issuance of the notes, up to an additional $25 million principal amount of notes, solely to cover over-allotments. The offering is expected to close on or about November 3, 2014, subject to customary closing conditions.

Help employers find you! Check out all the jobs and post your resume.

Back to news